While the pharmacology of SGLT2 inhibition is well understood, the mechanisms for its cardiovascular benefits are currently investigated: One proposed mechanism is the beneficial effect of glucose reduction on inflammatory processes in atherosclerosis. This evidence concerns the gene SLC5A2 and atherosclerosis.